Tarenflurbil appears to have no effect on cognition, activities of daily living in early Alzheimer’s. Medscape (12/15, Harrison) reported that, according to a study published Dec. 16 in the Journal of the American Medical Association, “tarenflurbil (Flurizan, Myriad Genetics), a gamma-secretase modulator, has no effect on cognition or activities of daily living (ADL)…in patients with mild” Alzheimer’s disease. In a “large phase 3, randomized, placebo-controlled trial” of 1,684 patients with mild Alzheimer’s disease, Boston University School of Medicine researchers found “virtually no difference between patients receiving active therapy vs. placebo controls at 18 months in either coprimary endpoints of cognition or ADL.” They also found “no differences between the two treatment groups on secondary outcome measures.”
Medscape (12/15, Harrison) reported that, according to a study published Dec. 16 in the Journal of the American Medical Association, “tarenflurbil (Flurizan, Myriad Genetics), a gamma-secretase modulator, has no effect on cognition or activities of daily living (ADL)…in patients with mild” Alzheimer’s disease. In a “large phase 3, randomized, placebo-controlled trial” of 1,684 patients with mild Alzheimer’s disease, Boston University School of Medicine researchers found “virtually no difference between patients receiving active therapy vs. placebo controls at 18 months in either coprimary endpoints of cognition or ADL.” They also found “no differences between the two treatment groups on secondary outcome measures.”
This entry was posted
on Thursday, December 17th, 2009 at 3:44 pm and is filed under Dimebon New Drug Information.
You can follow any responses to this entry through the RSS 2.0 feed.
Both comments and pings are currently closed.